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To rapidly identify carbapenemase producers in En-
terobacteriaceae, we developed the Carba NP test. The test 
uses isolated bacterial colonies and is based on in vitro hy-
drolysis of a carbapenem, imipenem. It was 100% sensitive 
and specifi c compared with molecular-based techniques. 
This rapid (<2 hours), inexpensive technique may be imple-
mented in any laboratory.
Multidrug resistance is emerging worldwide at an alarming rate among a variety of bacterial species, 
causing both community-acquired and nosocomial infec-
tions (1). Carbapenems, the last line of therapy, are now fre-
quently needed to treat nosocomial infections, and increas-
ing resistance to this class of β-lactams leaves the health 
care system with almost no effective drugs (1). However, 
reports of carbapenem-resistant Enterobacteriaceae have 
increased (2,3). Resistance may be related to association of 
a decrease in bacterial outer-membrane permeability, with 
overexpression of β-lactamases with no carbapenemase ac-
tivity or to expression of carbapenemases (2,4,5). Spread 
of carbapenemase producers is a relevant clinical issue be-
cause carbapenemases confer resistance to most β-lactams 
(2). Various carbapenemases have been reported in Entero-
bacteriaceae, such as the following types: Klebsiella pneu-
moniae carbapenemase (KPC; Ambler class A); Verona in-
tegron–encoded metallo-β-lactamase (VIM), imipenemase 
(IMP), New Delhi metallo-β-lactamase (NDM) (all Ambler 
class B); and oxacillinase-48 (OXA-48; Ambler class D) 
(2,4–6). In addition, carbapenemase producers are usually 
associated with many other non–β-lactam resistance deter-
minants, which give rise to multidrug- and pandrug-resis-
tant isolates (2,3,7).
Potential carbapenemase producers are currently 
screened fi rst by susceptibility testing, using breakpoint 
values for carbapenems (2,8). However, this technique is 
time-consuming, and many carbapenemase producers do 
not confer obvious resistance levels to carbapenems. There 
is a need for laboratories to search for carbapenemase pro-
ducers (9). Phenotype-based techniques for identifying in 
vitro production of carbapenemase, such as the modifi ed 
Hodge test, are not highly sensitive and specifi c (2,8,10). 
Detection of metallo-β-lactamase producers (IMP, VIM, 
NDM) and of KPC producers may be based on the in-
hibitory properties of several molecules but requires addi-
tional expertise and time (usually an extra 24–48 hours) 
(2,8,11,12). Furthermore, no inhibitors are available for de-
tecting OXA-48–type producers that are spreading rapidly, 
at least in northern Africa, the Middle East, and Europe (2). 
Molecular detection of carbapenemase genes remains cost-
ly and requires substantial expertise. Both the phenotype-
based techniques and molecular tests are time-consuming 
(at least 12–24 hours) and are poorly adapted to the clinical 
need for isolating patients rapidly to prevent nosocomial 
outbreaks.
We developed a novel test, described here, based on 
a technique designed to identify the hydrolysis of the b-
lactam ring of a carbapenem. This test is rapid, sensitive 
and specifi c, and adaptable to any laboratory in the world.
The Study
We included in the study 162 carbapenemase-pro-
ducing strains of various enterobacterial species isolated 
from clinical samples (e.g., blood cultures, urine, sputum) 
and of global origin (Table 1). This collection of strains 
also included 46 strains that were fully susceptible to car-
bapenems or showed a decreased susceptibility to car-
bapenems as a consequence of non–carbapenemase-based 
mechanisms (Table 2). Antibiograms were carried out for 
all strains on Mueller-Hinton agar (Becton Dickinson, Le 
Point de Chaix, France) according to guidelines of the Clin-
ical and Laboratory Standards Institute (13). The Carba NP 
(Carbapenemase Nordmann-Poirel) test was performed as 
follows. One calibrated dose (10 mL) of the tested strain 
directly recovered from the antibiogram was resuspended 
in a Tris-HCl 20 mmol/L lysis buffer (B-PERII, Bacte-
rial Protein Extraction Reagent; Thermo Scientifi c Pierce, 
Rockford, IL, USA), vortexed for 1 minute and further in-
cubated at room temperature for 30 minutes. This bacterial 
suspension was centrifuged at 10,000 × g at room temper-
ature for 5 minutes. Thirty μL of the supernatant, corre-
sponding to the enzymatic bacterial suspension, was mixed 
in a 96-well tray with 100 μL of a 1-mL solution made 
of 3 mg of imipenem monohydrate (Sigma, Saint-Quentin 
Fallavier, France), pH 7.8, phenol red solution, and 0.1 
mmol/L ZnSO4 (Merck Millipore, Guyancourt, France). 
The phenol red solution was prepared by mixing 2 mL of a 
phenol red (Merck Millipore) solution 0.5% (wt/vol) with 
16.6 mL of distilled water. The pH value was then adjusted 
to 7.8 by adding drops of 1 N NaOH. A mixture of the phe-
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nol red solution and the enzymatic suspension being tested 
was incubated at 37°C for a maximum of 2 hours. Test re-
sults were interpreted by technicians who were blinded to 
the identity of the patients who gave the samples.
All strains had previously been characterized for their 
β-lactamase content at the molecular level. MICs of car-
bapenems were determined by using the Etest (AB bioMéri-
eux, Solna, Sweden), and results were recorded according 
to US guidelines (Clinical and Laboratory Standards Insti-
tute), as updated in 2012 (13). The breakpoints used were 
those for imipenem and meropenem: susceptibility <1 μg/
mL, resistance >4 μg/mL, and for ertapenem, susceptibility 
<0.25 μg/mL, resistance > μg/mL.
When the Carba NP test was used, the color of the 
wells turned from red to orange or yellow (Figure 1) for all 
tested strains that were producing carbapenemases (Table 
1), whereas wells corresponding to bacterial extracts of 
isolates that did not produce carbapenemase remained red, 
whatever their level of carbapenem susceptibility (Table 
2). The color changed from red to yellow as early as 5–10 
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Table 1. Carbapenemase-producing clinical enterobacterial isolates subjected to the Carba NP test* 
Ambler class, 
carbapenemase type Species ȕ-Lactamase No. 
MIC range, mg/L Carba NP 
test result IMP ERT MER 
Class A        
 KPC-type Klebsiella pneumoniae KPC-2 27 0.5–>32 4–>32 1–>32 + 
 KPC-3 3 0.5–8 4–>32 1–8 + 
Klebsiella ozaenae KPC-3 1 >32 >32 2 + 
Escherichia coli KPC-2 5 0.5–4 0.5>32 0.5–2 + 
Enterobacter cloacae KPC-2 7 1–24 1.5–32 0.75–16 + 
Enterobacter aerogenes KPC-2 1 8 >32 8 + 
Citrobacter freundii KPC-2 2 8–>32 1.5–>32 1.5–3 + 
Serratia marcescens KPC-2 2 >32 >32 >32 + 
Salmonella spp. KPC-2 1 4 1 0.25 + 
 NMC-A E. cloacae NMC-A 1 16 >32 16 + 
 SME-type S. marcescens SME-1 1 32 4 12 + 
SME-2 1 32 4 12 + 
 GES-type E. cloacae GES-5 1 >32 >32 >32 + 
 IMI-type Enterobacter asburiae IMI-2 1 >32 >32 >32 + 
Class B        
 NDM-type K. pneumoniae NDM-1 16 0.5–>32 2–>32 1–>32 + 
 NDM-4 1 >32 >32 >32 + 
E. coli NDM-1 7 1–16 3–>32 1–16 + 
E. cloacae NDM-1 1 2 16 2 + 
C. freundii NDM-1 1 >32 >32 >32 + 
Providencia stuartii NDM-1 1 12 0.38 1.5 + 
Proteus rettgeri NDM-1 1 3 0.5 1.5 + 
 VIM-type K. pneumoniae VIM-1 15 0.5–>32 0.5–>32 0.38–
>32 
+ 
 VIM-19 1 8 16 4 + 
E. coli VIM-1 2 1.5–3 0.38–1.5 0.5–1 + 
 VIM-2 2 2–4 0.5–1.5 0.38–
0.5 
+ 
 VIM-19 1 8 16 4 + 
E. cloacae VIM-1 4 1–>32 0.38 to 
>32 
0.5–>32 + 
S. marcescens VIM-2 1 >32 >32 >32 + 
 IMP-type K. pneumoniae IMP-1 5 0.5–8 2–4 1–8 + 
 IMP-8 2 0.5–1 0.5–1 0.5 + 
E. coli IMP-1 2 0.5 3–4 0.5–1 + 
 IMP-8 1 6 8 3 + 
E. cloacae IMP-1 12 8–>32 >32 2–>32 + 
 IMP-8 2 0.75–
1.5 
0.5–1 0.5–1 + 
S. marcescens IMP-1 2 8–>32 >32 2–>32 + 
 IMP-11 1 8 >32 2 + 
Class D        
 OXA-48 type K. pneumoniae OXA-48 15 0.38–
>32 
0.38–>32 0.38–
>32 
+ 
 OXA-181 2 0.5-1 2–4 0.5–1 + 
E. coli OXA-48 6 0.38–3 0.5–16 0.12–1 + 
E. cloacae OXA-48 3 0.5–1 0.5–16 0.5–1.5 + 
P. rettgeri OXA-181 1 8 1 2 + 
*IMP, imipenem; ERT, ertapenem; MER, meropenem; KPC, K. pneumoniae carbapenemase; NMC-A, non–metallo-enzyme carbapenemase; SME, S.
marcescens enzyme; GES, Guiana extended-spectrum ȕ-lactamase; IMI, imipenem-hydrolysing ȕ-lactamase; NDM, New Delhi metallo-ȕ-lactamase; 
VIM, Verona integron–encoded metallo- ȕ-lactamase; IMP, imipenemase; OXA-48, oxacillinase-48. 
Carbapenemase-producing Enterobacteriaceae
minutes after incubation for KPC producers began. In most 
cases, incubation for 30 minutes was suffi cient for obtain-
ing a frank color change for carbapenemase producers. The 
test’s specifi city and sensitivity were 100% when results 
were compared with those from molecular-based meth-
ods, the reference standard for identifying carbapenemase 
genes. All tests were performed in triplicate, giving identi-
cal and reproducible results.
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Table 2. Non–carbapenemase-producing clinical enterobacterial isolates subjected to the Carba NP test* 
ȕ-Lactamase type, species ȕ-Lactamase No. 
MIC, mg/L Carba NP 
test result IMP ERT MER 
ESBLs       
 Klebsiella pneumoniae CTX-M-3 1 0.12 0.12 0.12 – 
 CTX-M-14 1 0.12 0.12 0.12 – 
 CTX-M-15 3 0.12 0.12 0.12 – 
 Escherichia coli CTX-M-1 1 0.12 0.12 0.12 – 
 CTX-M-3 1 0.12 0.12 0.12 – 
 CTX-M-14 2 0.12 0.12 0.12 – 
 CTX-M-15 2 0.12 0.12 0.12 – 
 VEB-1 1 0.12–0.25 0.12 0.12 – 
 Enterobacter cloacae CTX-M-15 3 0.12 0.12 0.12 – 
 VEB-1 1 0.12 0.12 0.12 – 
Plasmid-mediated AmpC or chromosomal AmpC + decreased membrane permeability    
 K. pneumoniae DHA-1 1 >32 >32 >32 – 
 DHA-2 1 0.12 0.5 0.12 – 
 E. coli Extended-spectrum cephalosporinase 1 0.12 0.12 0.12 – 
 CMY-2 1 0.12 0.12 0.12 – 
 CMY-10 1 0.12 0.38 0.12 – 
 DHA-1 1 0.12 0.12 0.12 – 
 ACC-1 1 0.12 0.12 0.12 – 
 Overexpressed cephalosporinase 1 16 >32 2 – 
 Proteus mirabilis ACC-1 1 0.25 0.12 0.12 – 
 E. cloacae Overexpressed cephalosporinase 7 0.12–16 1–>32 0.12–>32 – 
 Enterobacter aerogenes Overexpressed cephalosporinase 1 1 4 0.75 – 
 Morganella morganii Overexpressed cephalosporinase 2 1.5–2 0.12 0.5 – 
ESBL + decreased membrane permeability      
 K. pneumoniae CTX-M-15 8 0.25–8 1–>32 1–>32 – 
 SHV-28 1 1 4 1 – 
 SHV-2a 1 0.25 2 0.38 – 
 Enterobacter sakazakii CTX-M-15 1 0.25 1.5 0.25 – 
 Citrobacter freundii TEM-3 1 1 8 1 – 
*IMP, imipenem; ERT, ertapenem; MER, meropenem; ESBLs, extended-spectrum ȕ-lactamases. 
Figure 1. Representative results of the Carba NP test. The Carba NP 
test was performed with a noncarbapenemase producer (Escherichia 
coli producing the extended-spectrum β-lactamase CTX-M-15, 
upper panel) and with a carbapenemase producer (Klebsiella 
pneumoniae–producing New Delhi metallo-β-lactamase-1, 
lower panel) in a reaction medium without (left panel) and with 
(right panel) imipenem. Uninoculated wells are shown as controls. 
Photographs were taken after a 1.5-hour incubation. A color 
version of this fi gure is available online (wwwnc.cdc.gov/EID/
article/18/9/12-0355-F1.htm).
The Carba NP test perfectly differentiates carbapen-
emase producers (Table 1) from strains that are car-
bapenem resistant due to non–carbapenemase-mediated 
mechanisms, such as combined mechanisms of resistance 
(outer-membrane permeability defect associated with over-
production of cephalosporinase and/or extended-spectrum 
β-lactamases) or from strains that are carbapenem suscep-
tible but express a broad-spectrum β-lactamase without 
carbapenemase activity (extended-spectrum β-lactamase, 
plasmid and chromosome-encoded cephalosporinases) 
(Table 2). Interpretable positive results were obtained in <2 
hours, making it possible to implement rapid containment 
measures to limit the spread of carbapenemase producers.
Conclusions
The Carba NP test has multiple benefi ts. It is inexpen-
sive, rapid, reproducible, and highly sensitive and specifi c. 
It eliminates the need for using other techniques to identify 
carbapenemase producers that are time-consuming and less 
sensitive or specifi c. Using this accurate test would improve 
detection of patients infected or colonized with carbapen-
emase producers. The test has been routinely implemented 
in our microbiology department at Hôpital de Bicêtre and 
is giving excellent results (data not shown). In addition, use 
of the Carba NP test has greatly decreased the laboratory 
technicians’ workload and simplifi ed the clinical manage-
ment of potential carbapenemase producers.
This test could be used, for example, for directly test-
ing 1) bacteria obtained from antibiograms of blood culture 
or 2) bacterial colonies grown on culture media before an-
timicrobial drug susceptibility testing (Figure 2). Further 
studies will evaluate its clinical value for antimicrobial 
drug stewardship on bacteria isolated directly from clinical 
samples (Figure 2). When the Carba NP test is used for that 
purpose, we expect that the time to detect carbapenemase 
producers will decrease by at least 24 hours (Figure 2).
The test could also be used to quickly identify car-
bapenem-resistant isolates from fecal specimens screened 
for multidrug-resistant bacteria (Figure 2). This capability 
would be valuable in preventing outbreaks. To determine 
positive and negative predictive values of the test,  ad-
ditional evaluations will be required with strains isolated 
from clinical samples screened on different types of selec-
tive media. The use of the Carba NP test may also sup-
port novel antimicrobial drug development by facilitating 
patient enrollment in pivotal clinical trials. Its use as a 
home-made test may contribute to the global surveillance 
network.
The Carba NP test can effi ciently indicate the strains 
to be further tested by PCR or submitted to sequencing 
for a detailed identifi cation of the carbapenemase genes. 
Last, the test could be used in low-income countries that 
are large reservoirs for carbapenemase producers (2). It of-
fers a practical solution for detecting a main component 
of multidrug resistance in Enterobacteriaceae. Use of the 
Carba NP test will contribute to a better stewardship of 
carbapenems by changing the paradigm of controlling car-
bapenemase producers worldwide
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Figure 2. Strategy for identifi cation of carbapenemase-producing 
Enterobacteriaceae. The time needed to perform the test is 
indicated before each test. The number of fl asks indicates the 
degree of specialization needed to perform the test; the number 
of $ indicates the relative cost of each test. A color version of this 
fi gure is available online (wwwnc.cdc.gov/EID/article/18/9/12-
0355-F2.htm).
Carbapenemase-producing Enterobacteriaceae
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